Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
Trastuzumab deruxtecan produced an unprecedented response rate in heavily pretreated HER2-positive metastatic breast cancer patients who had all received prior trastuzumab emtansine, with durable responses and a median PFS exceeding 16 months. This single-arm phase 2 trial led to accelerated FDA approval in December 2019 and established T-DXd as a transformative agent in HER2-positive disease. Interstitial lung disease — including fatal cases — is the defining safety challenge that requires proactive monitoring in every patient.
Key Result: ORR — 60.9% (95% CI, 53.4 to 68.0); 112/184 patients responded; no formal hypothesis test vs a predefined null reported
Safety Signal: Interstitial lung disease in 13.6%, including 4 fatal (grade 5) cases (2.2%) — requires baseline and serial pulmonary monitoring
✅ Patient Eligibility
Must Have:
- HER2-positive (IHC 3+ or ISH-positive), centrally confirmed
- Metastatic or unresectable breast cancer
- Prior treatment with trastuzumab emtansine
- ECOG performance-status score 0 or 1
Cannot Have:
- Untreated or symptomatic brain metastases
- History of noninfectious ILD or pneumonitis requiring glucocorticoids
- Current or suspected ILD or pneumonitis
💊 Dosing Quick Guide
Treatment Regimen
Trastuzumab deruxtecan: 5.4 mg/kg IV every 3 weeks Cycle: 21 days Duration: Until disease progression, unacceptable toxicity, or withdrawal of consent
No comparator arm in this study.
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - Dose reduction levels: 5.4 → 4.4 → 3.2 mg/kg; discontinue if further reduction needed - ILD: Permanently discontinue for grade ≥2 ILD - Monitoring: CBC prior to each dose; pulmonary imaging at baseline and as clinically indicated
Mechanism: Trastuzumab deruxtecan is an antibody-drug conjugate comprising an anti-HER2 antibody linked to a topoisomerase I inhibitor payload (DXd) via a cleavable linker, enabling targeted intracellular drug delivery with a bystander killing effect [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | T-DXd 5.4 mg/kg (n=184) |
|---|---|
| Decreased neutrophil count | 20.7% |
| Anemia | 8.7% |
| Nausea | 7.6% |
| Decreased white-cell count | 6.5% |
| Decreased lymphocyte count | 6.5% |
| Fatigue | 6.0% |
⚠️ Interstitial Lung Disease: Any grade 13.6%, Grade 3 0.5%, Grade 4 0%, Fatal (grade 5) 2.2% (4 patients)
Key safety metrics:
- Discontinuations due to AE: 28 (15.2%)
- Dose reductions: 43 (23.4%)
- Dose interruptions: 65 (35.3%)
- Total deaths: 25 (including 4 attributed to ILD)
📊 Key Numbers
Median follow-up: 11.1 months (range, 0.7 to 19.9)
| Outcome | Result (95% CI) | Events / N |
|---|---|---|
| ORR (primary endpoint) | 60.9% (53.4–68.0) | 112/184 |
| Disease-control rate | 97.3% (93.8–99.1) | — |
| Clinical-benefit rate | 76.1% (69.3–82.1) | — |
| Median DOR | 14.8 months (13.8–16.9) | — |
| Median PFS | 16.4 months (12.7–NR) | — |
| 6-month OS | 93.9% (89.3–96.6) | — |
| 12-month OS | 86.2% (79.8–90.7) | — |
| Median time to response | 1.6 months (1.4–2.6) | — |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| DESTINY-Breast01 | T-DXd 5.4 mg/kg q3w | HER2+ mBC, post T-DM1, median 6 prior lines | ORR (ICR) | 60.9% (95% CI, 53.4–68.0) | [1] |
| HER2CLIMB | Tucatinib + trastuzumab + capecitabine vs control | HER2+ mBC, prior trastuzumab, pertuzumab, T-DM1 | PFS | see [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
HER2 IHC 3+: ORR 63% (95% CI, 55–71) vs IHC 1+/2+ ISH+: 46% (28–66) — numerically lower in lower-expressing tumors
Brain metastases (n=24): ORR 58% (95% CI, 37–78); median PFS 18.1 months — activity maintained, though small sample
Prior pertuzumab (Yes): ORR 64% (55–73) vs No: 54% (41–67) — responses seen regardless of pertuzumab history
ECOG 0: ORR 66% (56–75) vs ECOG 1: 56% (44–67) — consistent activity across performance status
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Accelerated approval Dec 2019 (HER2+ mBC, ≥2 prior anti-HER2 regimens); subsequently expanded to 2L (May 2022) and HER2-low (Aug 2022) [2] |
| EMA | Conditional marketing authorization Jan 2021; subsequently expanded |
⚠️ Verify current regulatory status before prescribing.
NCCN: Preferred regimen for HER2-positive mBC in the second-line setting (Category 1); recommended in later lines [3]
⚡ Grey Zones
- Single-arm design — no way to quantify benefit vs alternative therapies without randomized comparator
- Optimal sequencing vs tucatinib-based therapy after T-DM1 remains undefined by direct evidence
- Only 24 patients had brain metastases (treated, asymptomatic) — intracranial activity in active brain disease was not assessed
- No biomarker or clinical predictor of ILD risk identified — cannot risk-stratify patients before treatment
- Lower ORR in IHC 1+/2+ ISH-positive subgroup (n=28) raises questions about benefit by HER2 expression level
- Late-onset ILD (up to 535 days) may be undercharacterized with median 11.1 months follow-up
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510
- Enhertu (fam-trastuzumab deruxtecan-nxki) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743-754.
- Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.